/
Intellia Therapeutics, Inc. ( we, us, our, Intellia, or the Company ) is a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. Our mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments.
The business is unprofitable at the operating level (-651.67% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 16.9% YoY with margins expanding 271.4pp.
Negative free cash flow of -$396M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$66M
▲ +16.9% YoY
Net Income (TTM)
-$395M
▲ +20.5% YoY
Op. Margin
-636.56%
▲ +271.4pp YoY
ROIC
-42.47%
▼ -0.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$364M
▼ -11.6% YoY
Op. Cash Flow (TTM)
-$363M
▼ -13.1% YoY
Net Debt
-$295M
Net Cash Position
Cash & Equiv.
$376M
5Y CAGR: +3.1%
Continue Research